Q2 2016 EARNINGS
$18.5B

Q2 2016 SALES
$18.5B
INCREASE 3.9%

WORLDWIDE SALES INCREASE 7.9%

ADJUSTED DILUTED EARNINGS PER SHARE*
$1.74
INCREASE 1.8%

*Non-GAAP financial measure; non-GAAP financial measures should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. For full financial data and non-GAAP reconciliations, please refer to the Johnson & Johnson’s earnings release issued on July 19, 2016, available at http://www.investor.jnj.com/sales-earnings.cfm.

“We continue to see good momentum through the first half of 2016, delivering solid results in the second quarter, supported by the strong underlying growth across our enterprise. We saw notable strength in our Pharmaceuticals business due to the continued success of new products, and also achieved significant clinical milestones, advancing our robust pipeline. In our Consumer business, we are executing strategic portfolio decisions to expand our market leadership in key segments, and in Medical Devices, we are continuing to accelerate our growth driven by new product launches and transforming our commercial models.”

Excluding acquisitions/divestitures, on an operational basis, worldwide sales increased 3.9%.

Primary contributors:

$3.4B WORLDWIDE CONSUMER SALES

$8.7B WORLDWIDE PHARMACEUTICAL SALES

$6.4B WORLDWIDE MEDICAL DEVICES SALES


New products that contributed to growth:

WORLDWIDE CONSUMER SALES

Excluding acquisitions/divestitures, on an operational basis, worldwide sales increased 3.9%.

Primary contributors:

$3.4B WORLDWIDE CONSUMER SALES

New products that contributed to growth:

WORLDWIDE PHARMACEUTICAL SALES

Excluding acquisitions/divestitures and hepatitis C sales, on an operational basis, worldwide sales increased 12.8%.

Primary contributors:

$8.7B WORLDWIDE PHARMACEUTICAL SALES

New products that contributed to growth:

WORLDWIDE MEDICAL DEVICES SALES

Excluding acquisitions/divestitures, on an operational basis, worldwide sales increased 3.9%.

Primary contributors: